12:00 AM
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lucentis ranibizumab: Phase III started

Roche disclosed that last quarter its Genentech Inc. unit and Novartis began the Phase III HARBOR trial to evaluate 0.5 and 2 mg intravitreal injections of Lucentis...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >